We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Avigen (MM) | NASDAQ:AVGN | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1.32 | 0 | 01:00:00 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC
20549
_______________
FORM 8-K
CURRENT REPORT
Pursuant to Section
13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 26, 2009
AVIGEN, INC.
(Exact name of registrant as specified in charter)
Delaware | 000-28272 | 13-3647113 |
(State or other jurisdiction of | (Commission File Number) | (I.R.S. Employer Identification |
incorporation) | No.) |
1301 Harbor Bay Parkway
Alameda,
California 94502
(Address of principal
executive offices and zip code)
Registrants telephone number, including area code: (510) 748-7150
______________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01. Other Events.
On January 26, 2009, Avigen, Inc. issued a press release stating that it will review and consider the unsolicited tender offer made by BVF Acquisition LLC a wholly owned subsidiary of Biotechnology Value Fund, L.P. (collectively, BVF), to purchase all of the outstanding shares of Avigen Inc.s common stock for $1.00 per share.
A copy of the press release is attached as Exhibit 99.1 and is incorporated into this current report by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit No. | Description | |
99.1 | Press release issued by Avigen, Inc. on January 26, 2009. |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: January 26, 2009 | AVIGEN, INC. | |
By: | /s/ Andrew A. Sauter | |
Andrew A. Sauter | ||
Chief Financial Officer |
INDEX TO EXHIBITS
Exhibit No. | Description | |
99.1 | Press release issued by Avigen, Inc. on January 26, 2009. |
1 Year Avigen (MM) Chart |
1 Month Avigen (MM) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions